Moderna and Merck released results from a Phase 3 trial of their mRNA-based cancer vaccine, intismeran autogene, which demonstrated a 42% reduction in the risk of melanoma recurrence or death when combined with Merck's Keytruda, compared to Keytruda alone. This trial involved approximately 1,100 patients who had undergone surgery to remove their tumors.
Despite the promising clinical results, Moderna's stock fell as much as 25% following a leak of partial data, highlighting a disconnect between clinical expectations and investor sentiment.
Analysts noted that while the results were clinically meaningful, they fell short of some investor expectations, particularly when compared to earlier Phase 2 trial results that showed a 49% reduction in recurrence risk. The Phase 3 trial included a broader range of patient risk profiles, which may have influenced the lower efficacy results.
Experts believe that the vaccine could significantly improve outcomes for melanoma patients, potentially allowing them to avoid more complex treatments if the cancer does not return. However, questions remain about the long-term benefits and the vaccine's place in the evolving treatment landscape.
Moderna is also working towards regulatory approval for the vaccine, which could enter the market next year, while facing challenges related to the individualized nature of the therapy and the operational complexities involved in its production.
Overall, the trial results are seen as a major step forward in melanoma treatment, but the market's reaction underscores the cautious optimism surrounding the commercial potential of this innovative therapy